Case before high court involving Medicare payment to hospitals for discounted outpatient drugs does not directly involve manufacturers. But the scope of the ruling could have a profound effect on how much leeway the government has to address drug pricing using administrative tools.

Acting FDA commissioner Janet Woodcock’s latest appearance before Senate Health Committee shows once again she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.

Acting FDA Commissioner Woodcock’s latest appearance before Senate Health Committee shows once again she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.

Acting US FDA Commissioner Woodcock’s latest appearance before the Senate Health Committee shows once again that she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.

The drug pricing provisions in the Build Back Better bill include a number of exemptions and protections – each of which could have interesting consequences for pharmaceutical development.

CMS is famous for not being able to negotiate prices – and its payment for physician-administered drugs notoriously incentivizes higher prices. Yet, as the Biogen/Eisai Aduhelm experience shows, CMS can on occasion have a profound impact on product launches when it chooses to.